Sign Up to like & get
recommendations!
0
Published in 2018 at "Journal of Pharmaceutical and Biomedical Analysis"
DOI: 10.1016/j.jpba.2018.08.013
Abstract: HIGHLIGHTSSunitinib is a tyrosine kinase inhibitor and a candidate for TDM approach.Sunitinib and N‐desethyl sunitinib undergo light‐induced Z/E isomerization.Sample handling/analysis require light protection to preserve the active Z‐form.A fast and quantitative reconversion of the E‐…
read more here.
Keywords:
isomer;
clinical routine;
sunitinib;
therapeutic drug ... See more keywords